Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the Front-Line and Relapsed/Refractory Treatment of Hairy Cell Leukemia

David Jacob Hermel, Anna Ter-Zakarian, Jacob New, Alan Saven

Blood (2023) 142 (Supplement 1): 4413.

https://doi.org/10.1182/blood-2023-173218

Published: 2023

Journal Articles

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor, Omar Abdel-Wahab, Martin S. Tallman, Jae H. Park

Blood (2022) 140 (25): 2663–2671.

https://doi.org/10.1182/blood.2022016183

Published: 2022

Journal Articles

COVID-19 Pandemic Highlights Health Disparities in Latinos in San Diego

Elisa Quiroz, MD, David J Hermel, MD, Samantha R Bagsic, PhD, Carrie L. Costantini, MD, Anuj Mahindra, MD, Alan Saven, MD, Zhubin Gahvari, MD, Emily Nagler, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-143440

Published: 2020

Journal Articles

ABO/Rh Blood Group and COVID-19 Infection Severity

David J Hermel, MD, Elisa Quiroz, MD, Samantha R Bagsic, PhD, Carrie L. Costantini, MD, Alan Saven, MD, James R. Mason, MD, Zhubin Gahvari, MD, Emily Nagler, MD, Kathryn Bollin, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141702

Published: 2020

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Benjamin Durham, MD PhD, Young Rock Chung, MS, Sasinya Scott, MPH, Bartlomiej Getta, MBBS,, Eunhee Kim, PhD, Alan Saven, MD, Richard M. Stone, MD, Kanti R Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Neal Rosen, MD PhD, Ross L. Levine, MD, Michael Berger, PhD, Martin S Tallman, MD, Omar Abdel-Wahab

Blood (2015) 126 (23): 449.

https://doi.org/10.1182/blood.V126.23.449.449

Published: 2015

Journal Articles

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MS, Helen Won, MS, Eunhee Kim, PhD, Alan Saven, MD, Martha Wadleigh, MD, Richard M. Stone, MD, Jacqueline C. Barrientos, MD, Kanti R. Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Mario E Lacouture, MD, Neal Rosen, MD PhD, Michael Berger, PhD, Ross L Levine, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 24.

https://doi.org/10.1182/blood.V124.21.24.24

Published: 2014

Journal Articles

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

Joshua D. Rosenberg, Carol Burian, Jill Waalen, Alan Saven

Blood (2014) 123 (2): 177–183.

https://doi.org/10.1182/blood-2013-06-508754

Published: 2014

Journal Articles

Evaluation of Relative Dose Intensity (RDI) by Age in Patients (pts) with Non-Hodgkin Lymphoma (NHL) Receiving Pegfilgrastim and CHOP Based Chemotherapy

Lodovico Balducci, MD, May Mo, PhD, Steve Abella, MD, Alan Saven, MD

Blood (2012) 120 (21): 4880.

https://doi.org/10.1182/blood.V120.21.4880.4880

Published: 2012

Journal Articles

Beyond hairy cell: the activity of cladribine in other hematologic malignancies

Darren S. Sigal, Heather J. Miller, Ethan D. Schram, Alan Saven

Blood (2010) 116 (16): 2884–2896.

https://doi.org/10.1182/blood-2010-02-246140

Published: 2010

Journal Articles

In vivo targeting of B-cell lymphoma with glycan ligands of CD22

Weihsu C. Chen, Gladys C. Completo, Darren S. Sigal, Paul R. Crocker, Alan Saven, James C. Paulson

Blood (2010) 115 (23): 4778–4786.

https://doi.org/10.1182/blood-2009-12-257386

Published: 2010

Includes: Supplemental data

Journal Articles

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine

Darren S. Sigal, Robert Sharpe, Carol Burian, Alan Saven

Blood (2010) 115 (10): 1893–1896.

https://doi.org/10.1182/blood-2009-10-251645

Published: 2010

Journal Articles

Significant Activity of Dasatinib in CLL Demonstrated by Ex-Vivo Assay.

Darren S. Sigal, MD, Jorge Nieva, MD, Jonathan Diver, PhD, Elisa Romeo, PhD, Francis Lee, PhD, Alan Saven, MD

Blood (2007) 110 (11): 4197.

https://doi.org/10.1182/blood.V110.11.4197.4197

Published: 2007

Journal Articles

Optophoresis Accurately Predicts Response to Chemotherapy in CLL.

Patricia McNeeley, B.S., Alan Saven, M.D., Ilona Kariv, Ph.D., Jorge Nieva, M.D., Philippe Marchand, Ph.D., Jonathan Diver, Ph.D., Samuel Riccitelli, M.S., Michael Nerenberg, M.D.

Blood (2004) 104 (11): 4834.

https://doi.org/10.1182/blood.V104.11.4834.4834

Published: 2004

Journal Articles

Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.

Armando V. Mena-Duran, M.D, Lyudmila A. Bazhenova, M.D., Summanuna Togo, Ph.D, Jose Cervera-Zamora, M.D., Kelly J. Bethel, M.D., Jorge Nieva, M.D., Alan Saven, M.D., Tomas Mustelin, M.D. Ph.D., Miguel A. Sanz, M.D. Ph.D

Blood (2004) 104 (11): 3430.

https://doi.org/10.1182/blood.V104.11.3430.3430

Published: 2004

Journal Articles

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia

Jorge Nieva, Kelly Bethel, Alan Saven

Blood (2003) 102 (3): 810–813.

https://doi.org/10.1182/blood-2003-01-0014

Published: 2003

Journal Articles

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Blood (2002) 99 (10): 3530–3539.

https://doi.org/10.1182/blood.V99.10.3530

Published: 2002

Journal Articles

Cladribine Activity in Adult Langerhans-Cell Histiocytosis

Alan Saven, Carol Burian

Blood (1999) 93 (12): 4125–4130.

https://doi.org/10.1182/blood.V93.12.4125

Published: 1999

NARROW

A Single Arm Phase II Pilot Study of Low Dose Vemurafenib Plus Rituximab in the Front-Line and Relapsed/Refractory Treatment of Hairy Cell Leukemia

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

COVID-19 Pandemic Highlights Health Disparities in Latinos in San Diego

ABO/Rh Blood Group and COVID-19 Infection Severity

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

Evaluation of Relative Dose Intensity (RDI) by Age in Patients (pts) with Non-Hodgkin Lymphoma (NHL) Receiving Pegfilgrastim and CHOP Based Chemotherapy

Beyond hairy cell: the activity of cladribine in other hematologic malignancies

In vivo targeting of B-cell lymphoma with glycan ligands of CD22

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine

Significant Activity of Dasatinib in CLL Demonstrated by Ex-Vivo Assay.

Optophoresis Accurately Predicts Response to Chemotherapy in CLL.

Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Cladribine Activity in Adult Langerhans-Cell Histiocytosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only